Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human KRAS Stable Cell Line

    [CAT#: S01YF-1023-PY142]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    Kinase Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Family
    Kinases/Enzyme
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1;H23;H1792;H358;H441;H1299
    Target Classification
    Kinase Cell Lines
    Target Research Area
    CNS Research
    Related Diseases
    Schimmelpenning-Feuerstein-Mims Syndrome; Oculoectodermal Syndrome
    Gene ID
    Human:3845
    UniProt ID
    Human:P01116

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    The applications of KRAS include the development of oral drugs beyond the Rule of 5 for intracellular tough targets, the treatment of MSI-high colon cancer liver metastasis with immune-checkpoint inhibitors, the investigation of noncoding RNA profiles in KRAS-mutated colorectal cancer patients during treatment with oncolytic reovirus, and the maintenance of redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer. These studies highlight the potential of targeting KRAS in various therapeutic approaches and understanding its role in different cancer types.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human KRAS Stable Cell Line (S01YF-1023-PY142). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Morgan Garcia (Verified Customer)

    What are the recent advancements in targeting KRAS mutations in cancer? Sep 28 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    Recent developments include drugs targeting a broad range of KRAS alterations, including those with acquired resistance to KRASG12C inhibitors. Sep 28 2022

    chat Peyton Miller (Verified Customer)

    How does the KRAS p.G12C mutation affect lung cancer treatment? Oct 26 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    The KRAS p.G12C mutation in lung cancer can be effectively targeted by drugs like sotorasib, leading to durable clinical benefits. Oct 26 2022

    Published Data

    Fig.1 Silencing KRAS in NSCLC cell lines.

    In KRAS-mutant cell lines, pRS-KRAS infection led to a substantial decrease in KRAS protein expression when compared to both parental and pRS control vector-infected cells. Interestingly, in H1299 cells carrying the WT KRAS variant, infections with pRS, pRS-KRAS-C12, or pRS-KRAS-V12 had no discernible impact on KRAS protein levels.

    Ref: Sunaga, Noriaki, et al. "Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy." Molecular cancer therapeutics 10.2 (2011): 336-346.

    Pubmed: 21306997

    DOI: 10.1158/1535-7163.MCT-10-0750

    Research Highlights

    G Fakih, Marwan. et al. "Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C" The New England journal of medicine, 2023.
    This article discusses the impact of social media on mental health, specifically focusing on the influence on body image and self-esteem among adolescents. Research has shown a strong correlation between social media use and negative self-perception and body dissatisfaction. It also explores the potential positive effects of social media, such as promoting self-expression and positive body image. The findings highlight the need for further research and intervention strategies to mitigate the negative impact of social media on adolescent mental health.
    G Fakih, Marwan. et al. "Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C" The New England journal of medicine, 2023.
    Pubmed: 37870968   DOI: 10.1056/NEJMoa2308795

    Sánchez-Tilló, Ester. et al. "The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas." JCI insight, 2023.
    In CRC patients, mutations in the KRAS and BRAF genes result in distinct progression patterns. ZEB1, a protein known for inducing an epithelial-to-mesenchymal transition (EMT), is associated with worse outcomes in most carcinomas. A study using patient samples and mouse models revealed that ZEB1 plays opposite roles in KRAS- and BRAF-mutant CRCs. While ZEB1 is linked to a poorer prognosis and more aggressive tumors in KRAS-mutant CRCs, it is associated with better outcomes and decreased EMT in BRAF-mutant CRCs. This suggests that ZEB1 may function as a tumor suppressor in BRAF-mutant CRCs and highlights the importance of considering KRAS/BRAF mutations in targeting ZEB1 and EMT in personalized therapeutic approaches.
    Sánchez-Tilló, Ester. et al. "The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas." JCI insight, 2023.
    Pubmed: 37870961   DOI: 10.1172/jci.insight.164629

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare